Anemia of chronic disease medical therapy

Jump to navigation Jump to search

Anemia of chronic disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Anemia of chronic disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography or Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Anemia of chronic disease medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Anemia of chronic disease medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Anemia of chronic disease medical therapy

CDC on Anemia of chronic disease medical therapy

Anemia of chronic disease medical therapy in the news

Blogs on Anemia of chronic disease medical therapy

Directions to Hospitals Treating Anemia of chronic disease

Risk calculators and risk factors for Anemia of chronic disease medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Medical Therapy

  • The primary goal in the treatment of anemia of chronic disease it to treat the disease itself.

Supplemental iron:

  • Supplemental iron is recommended, as needed, to keep the transferrin saturation of above 20 percent and a serum ferritin level of ≥100 ng/mL.
  • Intravenous iron is more effective than oral iron.
  • Intestiona absorption of iron is greatly reduced due to hepcidin activity at intestinal lining.
  • Hepcidin induced entrampment of iran can be managed with parentral iron infusions.
  • In case of severe disease blood transfusion is recommended.
  • Stable patients can be given synthetically prepared erythropoiesis-stimulating agent such as erythropoietin.
  • EPO can be given once per week, while darbepoetin has an effectiveness equal to that of EPO when given once every two or three weeks. Supplemental iron should be given in all patients receiving EPO or darbepoetin in order to maintain a transferrin saturation ≥20 percent and a serum ferritin ≥100 ng/mL. Such use of erythropoiesis-stimulating agents is considered "unlabeled or investigational" in the United States and may not be reimbursed.


In majority of cases, treatment of the underlying disorder is more effective:

  • If the case is underlying malignancy, chemothearpy or radiotherapy may transiently exaxerbate anemia due to mylesuppressive effects, however in the long term, it leads to improvement.
  • If the cause is inflammatory disorder, such as rheumatoid arthritis the management of the disease with a disease-modifying antirheumatic drug (DMARD) improves the anemia significantly.
  • If the root cause of anemia is not found, a detailed search for inflammatory disorders such as inflammatory bowel disease and malignancy should be carried.
  • It is recommended to start with age-appropriate health screening.

References


Template:WikiDoc Sources